amodiaquine-artesunate (ASAQ)

ApprovedSmall molecule

CCenters for Disease Control and Prevention

amodiaquine-artesunate (ASAQ) is one of 60 small molecule programs targeting Plasmodium falciparum malaria. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plasmodium Falciparum MalariaActive, not recruiting

MalariaActive, not recruiting

Plasmodium Falciparum MalariaApproved

Active, not recruiting

MalariaPhase 3

Active, not recruiting

Competition

Competitive Landscape

479 competitors in Malaria

#DrugCompanyPhaseTrials

amodiaquine-artesunate (ASAQ)

CCenters for Disease Control and Prevention

Approved

2 2

Biltricide

Bayer

Preclinical

1 3

Stelara

Johnson & Johnson

Preclinical

—4

Hydroxychloroquine Sulfate

Novartis

Preclinical

—5

Iron

WWatson Pharmaceuticals

Preclinical

1 6

IV LBH589

Novartis

Preclinical

1 7

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

1 8

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

1 9

RTS,S/AS01E

GSK

Preclinical

4 10

Malarone

Medicines for Malaria Venture

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malaria2 trials

Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children

Completed·IInstitute of Tropical Medicine, Belgium·Phase 3·NCT00393679·4,112 enrolled

Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo

Completed·MMedecins Sans Frontieres, Netherlands·Phase 4·NCT02741024·288 enrolled

Plasmodium falciparum malaria1 trial

Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia

Completed·CCenters for Disease Control and Prevention·Phase 4·NCT06300970·352 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for amodiaquine-artesunate (ASAQ). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — amodiaquine-artesunate (ASAQ) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for amodiaquine-artesunate (ASAQ). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centers for Disease Control and Prevention company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CCenters for Disease Control and Prevention

amodiaquine-artesunate (ASAQ)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Malaria2 trials

Plasmodium falciparum malaria1 trial

References

Drug Info

Quick Facts

Related News